VJHemOnc is committed to improving our service to you

ICML 2017 | Diffuse large B-cell lymphoma lymphoma: Finding the best partner for durvalumab

VJHemOnc is committed to improving our service to you

Ulrich Jäger

Ulrich Jäger, MD from the Medical University of Vienna, Vienna, Austria gives an overview of his new Phase II trial on durvalumab (anti-PD-L1) combined with either R-CHOP or lenalidomide and R-CHOP in previously untreated high-risk diffuse large B-cell lymphoma (NCT03003520). His target population are patients who are essentially high risk and do not respond well to regular R-CHOP. The results of the trial will be widely anticipated as the drug combinations selected have not been explored yet. As the trial has just commenced, Dr Jager expects results will be available in 2 years’ time. This interview was recorded at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter